Last reviewed · How we verify
Prevention of herpes zoster (shingles) in adults 50 years of age and older — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| HZ/su VACCINE | hz-su-vaccine | Pfizer | Vaccine | Not specified |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Prevention of herpes zoster (shingles) in adults 50 years of age and older
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Prevention of herpes zoster (shingles) in adults 50 years of age and older:
- Prevention of herpes zoster (shingles) in adults 50 years of age and older treatment updates — RSS
- Prevention of herpes zoster (shingles) in adults 50 years of age and older treatment updates — Atom
- Prevention of herpes zoster (shingles) in adults 50 years of age and older treatment updates — JSON
Cite this brief
Drug Landscape (2026). Prevention of herpes zoster (shingles) in adults 50 years of age and older — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prevention-of-herpes-zoster-shingles-in-adults-50-years-of-age-and-older. Accessed 2026-06-10.
Related
- Prevention of herpes zoster (shingles) in adults 50 years of age and older full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing